EXACT Therapeutics AS (OSL:EXTX)
Norway · Delayed Price · Currency is NOK 0.6050
-0.1150 (-15.97%)
At close: Sep 11, 2026
EXACT Therapeutics AS Income Statement
Financials in millions NOK. Fiscal year is January - December.
Millions NOK. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Other Revenue | 0.08 | 0.06 | - | 0 | 0.45 | 0.05 |
| 0.08 | 0.06 | - | 0 | 0.45 | 0.05 | |
Revenue Growth | - | - | - | -99.02% | 774.07% | - |
Gross Profit | 0.08 | 0.06 | - | 0 | 0.45 | 0.05 |
Selling, General & Admin | 24.63 | 28.98 | 23.36 | 22.55 | 14.58 | 18.52 |
Research & Development | 36.18 | 40.54 | 18.52 | - | - | - |
Other Operating Expenses | 12.54 | 11.73 | 8.54 | 23.74 | 24.64 | 38.83 |
Operating Expenses | 77.06 | 84.94 | 52.85 | 48.38 | 41.23 | 59.16 |
Operating Income | -76.99 | -84.88 | -52.85 | -48.38 | -40.77 | -59.11 |
Interest Expense | -0.03 | -0.03 | -0.05 | -0.09 | -0.1 | -0.1 |
Interest & Investment Income | 1.24 | 2.62 | 0.92 | 0.95 | 0.48 | 0.34 |
Currency Exchange Gain (Loss) | -0.03 | -4.68 | -0.35 | -1.12 | 0.22 | 0.01 |
Other Non Operating Income (Expenses) | 0.01 | 0.01 | 0 | 0.25 | -0.4 | 0.27 |
EBT Excluding Unusual Items | -75.79 | -86.97 | -52.33 | -48.38 | -40.57 | -58.59 |
Pretax Income | -75.79 | -86.97 | -52.33 | -48.38 | -40.57 | -58.59 |
Income Tax Expense | - | - | - | -0.05 | -0.46 | - |
Net Income | -75.79 | -86.97 | -52.33 | -48.33 | -40.1 | -58.59 |
Net Income to Common | -75.79 | -86.97 | -52.33 | -48.33 | -40.1 | -58.59 |
Net Income Growth | - | - | - | - | - | - |
Shares Outstanding (Basic) | 88 | 63 | 35 | 32 | 30 | 30 |
Shares Outstanding (Diluted) | 88 | 63 | 35 | 32 | 30 | 30 |
Shares Change | 74.89% | 82.42% | 8.10% | 6.94% | 0.06% | 0.04% |
EPS (Basic) | -0.87 | -1.37 | -1.51 | -1.51 | -1.34 | -1.95 |
EPS (Diluted) | -0.87 | -1.37 | -1.51 | -1.51 | -1.34 | -1.95 |
EPS Growth | - | - | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | -67.06 | -72.31 | -82.05 | -47.39 | -34.1 | -56.74 |
Free Cash Flow Per Share | -0.77 | -1.14 | -2.37 | -1.48 | -1.14 | -1.89 |
Gross Margin | 100.00% | 100.00% | - | 100.00% | 100.00% | 100.00% |
Operating Margin | -98699.87% | -143859.87% | - | -1085224.09% | -8971.05% | -113674.66% |
Profit Margin | -97168.73% | -147402.80% | - | -1084201.23% | -8823.56% | -112673.43% |
Free Cash Flow Margin | -85976.39% | -122558.79% | - | -1062987.39% | -7503.15% | -109106.39% |
EBITDA | -74.01 | -81.81 | -51.08 | -46.75 | -39.3 | -57.66 |
D&A For EBITDA | 2.98 | 3.07 | 1.77 | 1.63 | 1.48 | 1.45 |
EBIT | -76.99 | -84.88 | -52.85 | -48.38 | -40.77 | -59.11 |
Revenue as Reported | 0.08 | 0.06 | - | 0 | 0.45 | 0.05 |